Environmental group Friends of the Earth, one of Oxitech's harsher critics, says the company has not "been open and honest with the local communities about the possible risks its technology pose." Helen Wallace of GeneWatch UK took that sentiment a step further when she said in a statement that Oxitec's Cayman experiment shows that the "British scientific establishment is acting like the last bastion of colonialism, using an overseas territory as a private lab."
In addition to these transparency complaints, opponents fret over a few lab-based studies showing that 3 percent of the Oxitec mosquitoes survived into adulthood despite possessing the self-destruct gene. Oxitec CEO Hadyn Parry tells New Times that this hasn't happened when they're released in the wild, nor is it likely that such mosquitoes can live long enough to transmit diseases. As for Oxitec's opaqueness, Parry says the company never denies an interview and welcomes reporters into its laboratories and has even shared confidential data with activist groups to quell further uproar.
Photo courtesy of Oxitec
Aedes aegypti is the only species of mosquito in South Florida capable of spreading dengue fever.
Photo courtesy of Oxitec
Oxitec's genetically modified mosquito larvae glow fluorescent green and red so researchers can track them.
Related Content
More About
According to Parry, the Cayman experiment worked well. He says the wild Aedes aegypti population plummeted by 80 percent after the Oxitec mosquitoes were released. Final data from the experiment has not been published in a journal. Parry says they are undergoing the peer review process for potential publication in Nature Biotechnology later this year.
Parry insists the company doesn't have any special interest in doing a release in the Florida Keys; it's Keys Mosquito Control that is pushing for the experiment. "From our point of view, we're working in a number of different places," he says. "We don't have a hit list saying that we'd like to work in this place or that place. If someone is interested and says, 'Hey, can you help us?' we say, 'Yes, of course we can.'"
The Keys is the only area in the States in talks with Oxitec about the use of modified mosquitoes. Even though the Keys are the sole site of locally acquired cases of dengue, some veteran mosquito experts in Florida are surprised that Doyle is picking up his predecessor's plan.
"Given that [Doyle is] brand new to the job, not even a year on, and is looking to take this step... yeah, we were surprised," says Phil Lounibos of the Florida Medical Entomology Laboratory, a Vero Beach-based facility that's part of the University of Florida's Institute of Food and Agricultural Sciences. "It's surprising because there is not supporting background evidence that we've seen showing that this will solve the dengue problem."
Even if the Cayman experiment did reduce Aedes aegypti populations by 80 percent, as Oxitec says, that might not be a great enough reduction to control the spread of dengue. Lounibos points to Singapore, where mosquito control efforts are extensive yet dengue persists. "Many people don't doubt that the Oxitec method can reduce abundance of the mosquito that carries dengue," he says. "But it doesn't necessarily mean that it will control dengue."
Lastly, Lounibos says, Oxitec's mosquitoes are not a "self-sustaining technology," meaning the Keys might end up making hefty payments to Oxitec to keep a steady stream of modified mosquitoes breeding with whatever population of wild females remains. "They're going to have to keep releasing these things," he says. "They're considering investing in this without knowing if the technology will get the end results."
Doyle has set aside $125,000 to cover the initial overhead of an experiment — converting a trailer into a lab, setting and monitoring traps, and paying for similar expenses. Doyle expects to spend half a million on Oxitec eggs the first full year, with the price dropping by half the second year. For the experiment, Oxitec has agreed to provide him with its mosquitoes for free during the first six months, and with good reason.
A successful test could provide a new customer for the fledgling company. More important, pulling off a release in the Keys would go a long way in removing the stereotype that genetically modified mosquitoes are a creepy, sci-fi solution. A release in the United States is a proverbial golden seal of approval, a mark of acceptance from one of the most stringent, red-taped regulatory bureaucracies in the world. Genetically modified mosquitoes could be pitched as a designer solution to dengue that doesn't need to be dropped from helicopters or dispersed from handheld foggers by uniformed men.
There's just one holdup. Genetically modified mosquitoes are so technologically advanced that no federal agency has claimed to have the jurisdiction to give Oxitec final approval for a release. Doyle likens them to a hover car: If Ford were to suddenly make a flying car available to consumers, would the Federal Aviation Administration, which regulates aircraft, have oversight, or would the Department of Transportation, which regulates roadways? Oxitec's proposal to release its creation has bounced through the USDA, the EPA, and the CDC, all of whom have claimed not to have jurisdiction, Doyle says. Now the FDA is reviewing Oxitec's application for what's called an "investigational new animal drug." Doyle says the FDA's decision could come in a few months or drag on for two years. If the agency ultimately denies the application, he could theoretically release Oxitec mosquitoes anyway because there's no law against it — but he says he wouldn't.